Successful administration of chimeric antigen receptor (CAR) T-cell therapy in patients requiring hemodialysis

Autor: Bradley D. Hunter, Daanish Hoda, Andy Nguyen, Launce Gouw, Bryan Huber, Ryan R. Jensen, Justine Preedit, Andrew Evens, Esther Huang, Jiyeon Park, Dennis L. Cooper
Jazyk: angličtina
Rok vydání: 2022
Předmět:
Zdroj: Experimental Hematology & Oncology, Vol 11, Iss 1, Pp 1-3 (2022)
Druh dokumentu: article
ISSN: 2162-3619
DOI: 10.1186/s40164-022-00266-1
Popis: Abstract Chimeric antigen receptor (CAR) T-cell therapy has revolutionized the treatment of relapsed/refractory B-cell malignancies. However, there is no data on the safety and efficacy of CAR T-cell therapy in patients with end stage renal disease (ESRD) requiring dialysis. In this report, we present two patients with DLBCL and ESRD who were successfully treated with different CAR T-cell products. Patient #1 is a 66 year-old woman with a history of HIV who was treated to complete response with axicabtagene ciloleucel with treatment complicated by grade 1 cytokine release syndrome (CRS) and grade 2 immune effector cell-associated neurolotoxicity syndrome (ICANS). Patient #2 is 52 year old woman whose ESRD was caused by ifosphamide toxicity and was treated to complete response with lisocabtagene maraleucel and did not experience either CRS or ICANS. Both patients received lymphodepletion chemotherapy with fludarabine and cyclophosphamide, which was dose-adjusted for ESRD with scheduled dialysis 12 h after each dose of lymphodepletion chemotherapy. Patients with DLBCL and ESRD can be safely administered both lymphodepletion chemotherapy and CAR T-cell therapy. Additionally, the fact that both patients achieved complete response to therapy suggests that CAR T-cell therapy should be strongly considered in patients with ESRD. Long-term follow up is needed to determine if therapy in this setting is of curative intent.
Databáze: Directory of Open Access Journals
Externí odkaz:
Nepřihlášeným uživatelům se plný text nezobrazuje